Cite
Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
MLA
Nishio, Makoto, et al. “Analysis of Central Nervous System Efficacy in the J-ALEX Study of Alectinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.” Lung Cancer (Amsterdam, Netherlands), vol. 121, July 2018, pp. 37–40. EBSCOhost, https://doi.org/10.1016/j.lungcan.2018.04.015.
APA
Nishio, M., Nakagawa, K., Mitsudomi, T., Yamamoto, N., Tanaka, T., Kuriki, H., Zeaiter, A., & Tamura, T. (2018). Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. Lung Cancer (Amsterdam, Netherlands), 121, 37–40. https://doi.org/10.1016/j.lungcan.2018.04.015
Chicago
Nishio, Makoto, Kazuhiko Nakagawa, Tetsuya Mitsudomi, Nobuyuki Yamamoto, Tomohiro Tanaka, Hiroshi Kuriki, Ali Zeaiter, and Tomohide Tamura. 2018. “Analysis of Central Nervous System Efficacy in the J-ALEX Study of Alectinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.” Lung Cancer (Amsterdam, Netherlands) 121 (July): 37–40. doi:10.1016/j.lungcan.2018.04.015.